Cryofocus Medtech (Shanghai) Co (6922.HK) Stock Price

Cryofocus Medtech (Shanghai) Co Ltd generates revenue through its cryoablation devices, including the Bladder Cryoablation System and the Endoscopic Clip for Anastomosis. The company sells these products to healthcare providers for treating urinary, respiratory, and digestive diseases such as bladder cancer, COPD, asthma, and airway stenosis, as well as cardiovascular conditions like atrial fibrillation and hypertension. Its portfolio includes approximately 15 product candidates in development and six commercialized medical consumables targeting the same therapeutic areas. The firm focuses on natural orifice transluminal endoscopic surgery and vascular interventional therapy, serving hospitals and clinics that specialize in urology, respiratory care, and cardiology. Revenue is derived from direct sales of its core devices and consumables to medical institutions within these specialized fields. Cryofocus Medtech's business model relies on a combination of established products and pipeline candidates to address multiple disease areas, with a strong emphasis on minimally invasive surgical solutions for both gastrointestinal and cardiovascular applications.